Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves antidepressant nasal spray
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Ketamine-derived nasal spray treating Phoenix patients with severe depression
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not without risk.
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
FDA approves Spravato nasal spray as a standalone treatment for depression in adults
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
Monthly Prescribing Reference
3d
Nasal Spray Formulation of Bumetanide Under FDA Review
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
Medical Xpress
9d
FDA approves nasal spray for treatment-resistant depression
The U.S. Food and
Drug
Administration has approved Spravato (esketamine) CIII
nasal
spray
for adults living with major ...
WXXI
9d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The U.S. Food and
Drug
Administration has expanded its approval of Spravato, an antidepressant
nasal
spray
. The
drug
...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Black boxes recovered
Los Angeles wildfire updates
Apologizes for old tweets
Top leaders asked to resign
Cause of death revealed
Court rules ban on gun sales
Recuses self from Act 10 suit
Olympic gold medalist dies
Sexual misconduct accusation
FDA approves painkiller
2 more victims in indictment
'As Tears Go By' singer dies
Asteroid may hit Earth
Michigan priest loses license
Confirmed interior secretary
Ground stop amid IT outage
Signs education orders
Hamas confirms death
Partners w/ US national labs
Ex-worker admits to theft
Blames DEI for crash
Shiffrin finishes 10th
Weekly jobless claims fall
DOJ sues to block deal
Nashville bids for franchise
S3 release date revealed
Ebola outbreak in Uganda
US economy grew 2.3%
Syria’s transitional pres
Wildfire erupts in NC
Deputy shooting sentence
Feedback